Highest-materiality recent filing
CARDIO-TTRansform trial did not meet primary composite endpoint of CV mortality and recurrent CV events vs placebo at Week 140.
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
FDA approved TRYNGOLZA (olezarsen) as adjunct to diet to reduce triglycerides and risk of acute pancreatitis in adults with sHTG (TG ≥500 mg/dL).
Ionis olezarsen OLE data: liver fat returns toward baseline after 24 months; 90%+ retention
Mean hepatic fat fraction (HFF) levels returned toward baseline after 24 months of olezarsen 80 mg in CORE-OLE study of severe hypertriglyceridemia.
19% functional cure rate (233/1,220) vs 0% placebo (p<0.001) in overall population (HBsAg ≤3000 IU/mL).
Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B
Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.
Ionis zilganersen meets primary endpoint in Alexander disease; PDUFA Sept 22, 2026
Primary endpoint met: gait speed stabilized vs control at Week 61 (LS mean diff 33.3%, p=0.041) in patients ≥5 years.
Ionis FY2025 total revenue $944M (+34% YoY); guides 2026 rev $800-825M, op loss $500-550M
FY2025 total revenue $944M (2024: $705M); Q4 revenue $203M.
TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.
Bepirovirsen Phase 3 positive: primary endpoint met, functional cure rates superior to SOC
Over 1,800 patients enrolled in two Phase 3 studies (B-Well 1 & 2) across 29 countries.
Ionis closes $770M 0% convertible notes offering, repurchases $200M of 2026 notes
Issued $770M aggregate principal of 0.00% Convertible Senior Notes due 2030 (including full greenshoe), net proceeds ~$751.2M.
Ionis reports Phase 3 olezarsen results: 72% TG reduction, 85% fewer pancreatitis events
Primary endpoint met: up to 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months (p<0.001).
Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength
TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.
Primary endpoint met: gait speed improved 33.3% vs control (p=0.0412) at week 61 in 50 mg cohort.
Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)
FDA approves Ionis' DAWNZERA (donidalorsen) for HAE prophylaxis in patients 12+
First and only RNA-targeted HAE medicine; self-administered every 4 or 8 weeks via autoinjector.
Ionis Q2 revenue doubles to $452M; raises FY 2025 guidance, TRYNGOLZA sales $19M
Q2 total revenue $452M (up from $225M); GAAP income from ops $140M vs loss $66M year ago.
Ionis announces positive Phase 3 Essence study of olezarsen in moderate hypertriglyceridemia
Primary endpoint met: placebo-adjusted 61% (80 mg) and 58% (50 mg) reduction in TG at 6 months (p<0.0001).
Ionis Q1 revenue up 10% to $132M; TRYNGOLZA brings $6M, guidance raised >20%
Revenue $132M (+10% YoY); TRYNGOLZA product sales $6M; royalty revenue $64M (SPINRAZA $48M, WAINUA $9M).
Ionis licenses sapablursen to Ono for $280M upfront, up to $660M milestones and mid-teen royalties
$280M upfront payment; up to $660M in development, regulatory and sales milestones.
Ionis Q4 rev $227M, FY rev $705M; 2025 guidance rev >$600M, non-GAAP op loss <$495M
FY2024 total revenue $705M exceeded guidance; operating loss $475M GAAP, $345M non-GAAP.
FDA approves Ionis' Tryngolza (olezarsen) as first treatment for familial chylomicronemia syndrome
Phase 3 Balance trial: placebo-adjusted mean triglyceride reduction 42.5% at 6 months (p=0.0084), 57% at 12 months.
Ionis Q3 revenue $134M (-7% YoY); reaffirms 2024 P&L guidance; increases cash guidance to $2.2B
Q3 total revenue $134M vs $144M YoY; commercial revenue $76M, R&D revenue $58M.
Ionis raises ~$500M in public offering of 11.5M shares at $43.50/share
Sold 11.5M shares of common stock at $43.50 per share; gross proceeds ~$500.3M.
Ionis proposes public offering of common stock; no size or price disclosed
Filed preliminary prospectus supplement on Sep 9, 2024 for a registered underwritten public offering of common stock.
Ionis Q2 revenue $225M (+20% YoY); operating loss narrows to $66M; key pipeline milestones
Total revenue $225M (up 20% YoY); loss from operations $66M vs $91M loss in Q2 2023; non-GAAP loss from ops $35M.
Ionis expands Otsuka license for donidalorsen in Asia-Pacific; $20M upfront
Otsuka gains exclusive rights to commercialize donidalorsen (HAE) in Asia-Pacific; Ionis retains US rights.
Ionis reports positive Phase 3 results for donidalorsen in HAE; 81% attack reduction vs placebo
Donidalorsen met primary endpoint: 81% lower monthly HAE attack rate with Q4W dosing vs placebo (p<0.001) over 24 weeks.
Ionis Q1 revenue $119M, loss $150M; WAINUA launch delivers $1M royalty; olezarsen NDA filed for FCS
Q1 total revenue $119M, down 9% YoY from $131M; GAAP operating loss $150M vs $114M prior year.
Ionis Phase 3 Balance study of olezarsen meets primary endpoint; reduces acute pancreatitis in FCS
Olezarsen 80 mg reduced fasting triglycerides by 44% vs placebo at 6 months (p<0.001).
Ionis announces Kyle Jenné returns as EVP Commercial; Onaiza Cadoret-Manier departs
Kyle Jenné rejoins as executive vice president, commercial, effective Feb 29, 2024.
Ionis Q4 revenue $325M, up 114%; WAINUA approved; 2024 guidance: revenue >$575M
Q4 total revenue $325M (up 114% YoY); full year revenue $788M (up 34%); Q4 operating loss narrowed to $6M from $208M.
Ionis announces positive Phase 3 results for donidalorsen in HAE; NDA submission planned
Donidalorsen met primary endpoint: significant reduction in HAE attack rate for Q4W (p<0.001) and Q8W (p=0.004) vs placebo.
FDA approves Ionis/AstraZeneca WAINUA (eplontersen) for hATTR polyneuropathy
Approval based on Phase 3 NEURO-TTRansform 35-week interim; co-primary endpoints of serum TTR and mNIS+7 and Norfolk QoL-DN showed sustained benefit.
Ionis licenses donidalorsen European rights to Otsuka; $65M upfront, tiered royalties
Otsuka receives exclusive European commercialization rights to donidalorsen (HAE prophylactic).
Ionis Q3 2023 revenue $144M, net loss $143M; eplontersen on track for Dec 2023 U.S. approval
Total revenue $144M (-10% YoY); SPINRAZA royalties $67M flat; R&D revenue $60M down from $87M.
Ionis signs $60M upfront deal with Roche for two RNA programs for Alzheimer's and Huntington's
Ionis receives $60M upfront; Roche gains exclusive worldwide rights to develop and commercialize two undisclosed RNA-targeting medicines.
Ionis reports positive Phase 3 olezarsen results; 100% reduction in pancreatitis in FCS
Olezarsen 80 mg achieved primary endpoint with significant triglyceride reduction vs placebo (p=0.0009) at six months.
Ionis Q2 2023 revenue up 40% to $188M; eplontersen PDUFA set for Dec 22, 2023
Total revenue $188M in Q2 (+40% YoY); operating loss $91M GAAP, $64M non-GAAP.
Notified Sudberry Development of termination under Section 2.3 of Lease due to failure to commence grading by July 31, 2023.
Ionis and Novartis expand Lp(a) collaboration; Ionis gets $60M upfront for next-gen therapy
Ionis receives $60 million upfront from Novartis for next-generation Lp(a) compound.
appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026
the Company also appointed Peter N. Reikes as a member of the Company’s Board effective June 4, 2026
On June 12, 2025, the Company issued a press release announcing that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed Dr. Richard Geary Ph.D. in the role of executive vice president and chief development officer beginning in January 2026.
On June 12, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Richard Geary Ph.D., executive vice president and chief development officer, will retire effective January 2026.
Kyle Jenné has rejoined Ionis as executive vice president, commercial
Onaiza Cadoret-Manier, executive vice president, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.
On December 14, 2023, the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”) appointed Michael Yang as a member of the Company’s Board effective immediately.
On July 15, 2022, Frederick Muto, a member of the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”), notified the Company that he is retiring from the Company’s Board effective July 15, 2022.
On November 19, 2021, Peter N. Reikes, a member of the Board of Directors (“Board”) and Finance Committee of the Board of Ionis Pharmaceuticals, Inc. (the “Company”), notified the Company that he is resigning from the Company’s Board effective November 21, 2021.
Max materiality 0.95 · Median 0.75 · Most common event other_material